London, November 15 (ots/PRNewswire) - - Optimal Adjuvant Therapy Should Now Include an AI Such as 'Arimidex' (anastrozole) in Order to Reduce the Risk of Tumour Recurrence Today, the American Society of Clinical Oncology (ASCO) Technology Assessment Panel announced a fundamental change to its internationally recognised guidance on the use of ...
Turku, Finland, November 12 (ots/PRNewswire) - - The Partnership Agreement on the First Indication (Pathological Gambling) Could be Valued at up to USD 13.2 Million Plus Royalties - Somaxon to Initiate a Phase III Clinical Development Program in Pathological Gambling Biotie Therapies Corp. and Somaxon ...
New Orleans, November 10 (ots/PRNewswire) - - Analysis of 30 Adverse Event Risk Factors Offers New Insights for Patient Care Data presented today at the 2004 American Heart Association Scientific Sessions further documented the low incidence of Major Adverse Cardiac Events (MACE) and stent thrombosis ...
Edmonton, Canada, November 3 (ots/PRNewswire) - Isotechnika Inc. announced today that the Company has successfully completed the multiple ascending dose study for its lead immunosuppressive drug, ISA247. The multiple ascending dose (MAD) study for ISA247 that commenced on June 3, 2004 involved a total of 43 subjects. The study, conducted by SFBC Anapharm in ...
Vienna, Austria, November 2 (ots/PRNewswire) - - Significant Advances in the Clinical Development of Yondelis(TM) and Aplidin(R) PharmaMar, the biopharmaceutical company specialising in cancer therapy, presented new data from its two lead drugs, Yondelis(TM) and Aplidin(R), at the 29th European Society for Medical Oncology Congress (ESMO) held in Vienna, Austria from 29 October to 2 November 2004. Data ...
London, Ontario, November 1 (ots/PRNewswire) - In this week's issue of the Lancet Neurology, glatiramer acetate, known as Copaxone(R), was subjected to an independent review. The systematic review, called a Cochrane Review, performed by Dr. Luca Munari and colleagues, challenges the claims of benefit from previous industry-based publications. A convincing ...
Washington, November 1 (ots/PRNewswire) - New data from a pivotal Phase 3 study (RESIST-1) demonstrate that a statistically significant greater percentage of HIV-positive patients taking a tipranavir-based regimen achieved a treatment response versus those taking a regimen containing one of several marketed protease inhibitors (PIs). Treatment response in this study ...
Indianapolis, November 1 (ots/PRNewswire) - New data presented today confirm that advanced lung cancer patients can look forward to better-quality survival when treated with Alimta(R) (pemetrexed), a newly approved anticancer agent in the European Union compared with Taxotere(R) (docetaxel). Eli Lilly and Company ...
Basel, Switzerland (ots/PRNewswire) - - New Treatment Option the First to Help Postmenopausal Women With Early Breast Cancer Remain Cancer-Free Following Adjuvant Tamoxifen Therapy Femara(R) (letrozole) is the first therapy approved by the U.S. Food and Drug Administration (FDA) for the extended adjuvant treatment of postmenopausal women with early breast ...
Shire Pharmaceuticals Group Plc
St Louis, Missouri (ots/PRNewswire) - Shire Pharmaceuticals Group plc (NASDAQ: SHPGY, LSE: SHP.L, TSE: SHQ CN) announced that long-term treatment with FOSRENOL(R) (lanthanum carbonate) for up to five years, shows no deterioration in bone health according to new data presented today for the first time at the ...
Vienna, Austria (ots/PRNewswire) - - Medical experts and patients call for early diagnosis to improve chances of cure According to leading oncologists, speaking today at the European Society for Medical Oncology, findings from the MOSAIC study represent a significant step forward in providing colon ...
Madrid (ots/PRNewswire) - PharmaMar today announced that Kahalalide F (KF), its marine-origin compound, has entered into Phase II trials for the treatment of patients with severe psoriasis. KF is currently undergoing Phase II clinical trials in various tumours: melanoma, non-small lung cancer and hepatocarcinoma. During the Phase I clinical trials on ...
Madrid (ots/PRNewswire) - The Zeltia Group (ZEL.MC) today reported financial results for the third quarter and the nine months ended September 30, 2004. Q3 Highlights Financial: - Group sales up 6.3% to Euro 63.7million (Euro 59.9 million 9M03) - Losses before interest and tax narrowed significantly to Euro 2.3 million (Euro 5.5 million 9M03) - R&D down by 28.9% to Euro 27.8 million reflecting a ...
Prague, Czech Republic (ots/PRNewswire) - - Patients call for better standards of care People with psoriasis are still being treated as social outcasts according to the results of a new international survey announced on World Psoriasis Day. This has led for calls from a leading patient advocate, Lars ...
Basel, Switzerland (ots/PRNewswire) - - New M3 selective receptor antagonist treatment for overactive bladder Novartis Pharma AG announced today that Emselex(R) (darifenacin hydrobromide), 7.5 mg and 15 mg, has been granted Marketing Authorization by the European Commission for the treatment of overactive bladder (OAB) in all 25 European member states as ...
Montreal, Canada (ots/PRNewswire) - Galileo Genomics announced today the completion of a panel of approximately 80,700 SNP markers covering 99.8% of the sequenced genome at a density optimised for the Quebec French Canadian Founder Population (QFP). This panel, known as the Quebec Linkage Disequilibrium Map ...
Espoo, Finland (ots/PRNewswire) - - Parkinson's Patients who Require the Start of Levodopa Therapy may be Eligible to Participate in This Study Orion Pharma and Novartis announced that they are launching STRIDE-PD (STalevo Reduction In Dyskinesia Evaluation). This major study in Parkinson's disease (PD) ...
Basel, Switzerland (ots/PRNewswire) - - Parkinson's Patients Who Require the Start of Levodopa Therapy May Be Eligible to Participate in This Study Novartis and Orion Pharma announced that they are launching STRIDE-PD (STalevo Reduction In Dyskinesia Evaluation). This major study in Parkinson's disease ...
Ingelheim, Germany (ots/PRNewswire) - Boehringer Ingelheim today announced the submission of a Marketing Authorisation Application (MAA) to the European Medicines Agency (EMEA) for tipranavir. Simultaneously the documentation was submitted to the FDA. Tipranavir is a non-peptidic protease inhibitor (NPPI) for ...
Basel, Switzerland (ots/PRNewswire) - Roche announced today that its innovative cancer drug, Avastin has received a positive recommendation from the European Committee for Medicinal Products for Human Use (CHMP). The CHMP has recommended that Avastin (bevacizumab) in combination with intravenous ...
Ann Arbor, Michigan (ots/PRNewswire) - - Aastrom's Proprietary TRCs to be Utilized to Build New Bone Tissue for Dental Implants -- Aastrom Biosciences, Inc. (NasdaqSC: ASTM), and the Institut de Terapia Regenerativa Tissular (ITRT) announced today that they have initiated patient enrollment in a clinical ...
Bothell, Washington and Indianapolis, Indiana (ots/PRNewswire) - - Third Quarter 2004 U.S. sales of Cialis exceed US$70 million - Lilly ICOS LLC (Lilly ICOS) (NYSE: LLY and Nasdaq: ICOS) is releasing its financial results for the three and nine months ended September 30, 2004. Worldwide sales of Cialis(R) (tadalafil) in the third quarter of 2004 were ...
Basel, Switzerland (ots/PRNewswire) - Key figures First nine months Nine months 2004 Nine months 2003 % Change USD m % of sales USD m % of sales USD lc[1] Sales 20 669 18 134 14 9 Pharmaceutical 11 641 ...
Edmonton, Alberta (ots/PRNewswire) - Isotechnika Inc. announced today the appointment of Patrice R. Debregeas to its board of directors. As Chairman, CEO and President of Ethypharm S.A, the leading drug delivery company in Europe, Mr. Debregeas brings extensive international experience in the pharmaceutical ...
Buenos Aires, Argentina (ots/PRNewswire) - -- Additional Analysis Shows Couples Agree Cialis Improves Erectile Function in Men with ED and Increases Satisfaction with Sexual Experience -- An international study conducted in 21 countries showed that 82 percent of men with ED who were treated with 20 mg ...
Ann Arbor, Michigan (ots/PRNewswire) - Aastrom Biosciences, Inc. (NasdaqSC: ASTM) and the Institut de Terapia Regenerativa Tissular (ITRT) announced today that their clinical trial in Barcelona, Spain will be expanded based on initial results from the first phase of patient treatments. The trial involved 5 ...
Copenhagen, Denmark (ots/PRNewswire) - Tamas Bartfai, Ph.D., is the director of the Harold L. Dorris Neurological Research Center at The Scripps Research Institute, La Jolla, CA. In addition, he holds the Harold L. Dorris Chair in Neuroscience. Professor Bartfai is former head of central nervous system research at Hoffman-La Roche where he served as Senior Vice ...
Lausanne (ots) - IMD has been ranked as one of the world's Top 5 business schools by two of the most prestigious MBA ranking bodies: BusinessWeek and The Economist Intelligence Unit (EIU). As previously announced the 2004 Wall Street Journal survey of corporate recruiters ranked IMD as the No. 1 international ...
Basel, Switzerland (ots/PRNewswire) - Today, HIV drug Fuzeon (enfuvirtide or T-20) was awarded the 2004 International Prix Galien for the most innovative new medicine. Fuzeon was selected out of 12 major new drugs in all therapeutic areas which each won national awards. Since 1970 Roche has won a total of 24 ...
Wolters Kluwer Health, Pharma Solutions
Chester, England (ots/PRNewswire) - - Accepts Prestigious 2004 'Investors in People' Award Wolters Kluwer Health, Pharma Solutions business unit today announced that Adis International was named a 2004 "Investor in People" by the Investors in People UK Recognition Panel. The London-based organization assesses corporate business practices against a national ...